deltatrials
Completed PHASE3 NCT00868634

Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer

Capecitabine and Bevacizumab ± Vinorelbine as 1st Line Treatment in HER-2 Negative Metastatic or Locally Advanced Inoperable Breast Cancer Patients

Sponsor: Arbeitsgemeinschaft fur Internistische Onkologie

Conditions Metastatic Breast Cancer
Interventions bevacizumab capecitabine vinorelbine
Updated 5 times since 2017 Last updated: Aug 29, 2016 Started: Feb 28, 2009 Primary completion: Mar 31, 2014 Completion: Oct 31, 2015

Listed as NCT00868634, this PHASE3 trial focuses on Metastatic Breast Cancer and remains completed. Sponsored by Arbeitsgemeinschaft fur Internistische Onkologie, it has been updated 5 times since 2009, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Feb 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Arbeitsgemeinschaft fur Internistische Onkologie
  • Arbeitskreis Klinische Studien
  • Roche Pharma AG
  • iOMEDICO AG
Data source: iOMEDICO AG

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Hamburg, Germany